NASDAQ:EXEL - Exelixis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.61 +0.28 (+1.45 %) (As of 05/20/2019 04:00 PM ET)Previous Close$19.33Today's Range$19.0250 - $19.7452-Week Range$13.42 - $25.31Volume2.49 million shsAverage Volume3.69 million shsMarket Capitalization$5.92 billionP/E Ratio13.71Dividend YieldN/ABeta2.06 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. Receive EXEL News and Ratings via Email Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXEL Previous Symbol CUSIP30161Q10 CIK939767 Webwww.exelixis.com Phone650-837-7000Debt Debt-to-Equity Ratio0.01 Current Ratio7.56 Quick Ratio7.48Price-To-Earnings Trailing P/E Ratio13.71 Forward P/E Ratio21.32 P/E Growth0.39 Sales & Book Value Annual Sales$853.83 million Price / Sales6.93 Cash Flow$1.5392 per share Price / Cash Flow12.74 Book Value$4.59 per share Price / Book4.27Profitability EPS (Most Recent Fiscal Year)$1.43 Net Income$690.07 million Net Margins75.97% Return on Equity37.21% Return on Assets33.14%Miscellaneous Employees484 Outstanding Shares301,767,000Market Cap$5.92 billion Next Earnings Date8/7/2019 (Estimated) OptionableOptionable Exelixis (NASDAQ:EXEL) Frequently Asked Questions What is Exelixis' stock symbol? Exelixis trades on the NASDAQ under the ticker symbol "EXEL." How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.24 EPS for the quarter, hitting analysts' consensus estimates of $0.24. The biotechnology company earned $215.49 million during the quarter, compared to analysts' expectations of $206.06 million. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. The business's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.40 earnings per share. View Exelixis' Earnings History. When is Exelixis' next earnings date? Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Exelixis. What price target have analysts set for EXEL? 8 analysts have issued 12 month target prices for Exelixis' stock. Their predictions range from $22.00 to $48.00. On average, they anticipate Exelixis' share price to reach $29.2857 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for Exelixis. What is the consensus analysts' recommendation for Exelixis? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis. Has Exelixis been receiving favorable news coverage? Media headlines about EXEL stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Exelixis earned a news impact score of -1.6 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the next few days. Who are some of Exelixis' key competitors? Some companies that are related to Exelixis include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL). What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Incyte (INCY), Gilead Sciences (GILD), Intel (INTC), Celgene (CELG), BioMarin Pharmaceutical (BMRN) and Puma Biotechnology (PBYI). Who are Exelixis' key executives? Exelixis' management team includes the folowing people: Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50) Who are Exelixis' major shareholders? Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.23%), FMR LLC (6.84%), AQR Capital Management LLC (5.25%), Meditor Group Ltd (5.03%), JPMorgan Chase & Co. (3.30%) and Renaissance Technologies LLC (3.17%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis. Which institutional investors are selling Exelixis stock? EXEL stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Meditor Group Ltd, FMR LLC, Rhenman & Partners Asset Management AB, Neuberger Berman Group LLC, Penn Capital Management Co. Inc., AJO LP and First Trust Advisors LP. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley and Vincent T Marchesi. View Insider Buying and Selling for Exelixis. Which institutional investors are buying Exelixis stock? EXEL stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Wells Fargo & Company MN, Frontier Capital Management Co. LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Great Lakes Advisors LLC and Fiera Capital Corp. View Insider Buying and Selling for Exelixis. How do I buy shares of Exelixis? Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Exelixis' stock price today? One share of EXEL stock can currently be purchased for approximately $19.61. How big of a company is Exelixis? Exelixis has a market capitalization of $5.92 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe. What is Exelixis' official website? The official website for Exelixis is http://www.exelixis.com. How can I contact Exelixis? Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected] MarketBeat Community Rating for Exelixis (NASDAQ EXEL)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 401 (Vote Outperform)Underperform Votes: 347 (Vote Underperform)Total Votes: 748MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: The basics of gap trading strategies Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.